Please login to the form below

Not currently logged in
Email:
Password:

Zarxio

This page shows the latest Zarxio news and features for those working in and with pharma, biotech and healthcare.

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance

Previous launches have included its Glatopa version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate) and Zarxio, a variant of Amgen’s Neupogen (filgrastim).

Latest news

More from news
Approximately 3 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    Having long lagged behind its European counterparts, the FDA approved in March its first ever biosimilar in the form of Sandoz's Zarxio - a version of Amgen's white cell stimulator ... Granted, it took less than two months for Amgen to secure an

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics